---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-065781"
form_type: "8-K"
ticker: "IOVA"
cik: "0001425205"
company_name: "IOVANCE BIOTHERAPEUTICS, INC."
filed_at: "2025-07-03T23:59:59+00:00"
generated_at: "2026-05-18T09:26:20.804775+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Iovance CFO Bellemin departs effective June 30; SVP Finance Rosinack named interim CFO

## Summary
- CFO Jean-Marc Bellemin's resignation accelerated from July 10 to June 30, 2025 by mutual agreement.
- Matthew W. Rosinack appointed interim Principal Financial Officer and Principal Accounting Officer effective June 30, 2025.
- Rosinack has been SVP, Finance since Sept 2021; prior roles at Berkeley Lights, ZELTIQ Aesthetics, FormFactor, and PwC.
- No arrangements, family relationships, or transactions requiring disclosure in connection with Rosinack's appointment.

## SEC filing metadata
- accession: 0001104659-25-065781
- form_type: 8-K
- ticker: IOVA
- cik: 0001425205
- company_name: IOVANCE BIOTHERAPEUTICS, INC.
- filed_at: 2025-07-03T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1425205/000110465925065781/0001104659-25-065781-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1425205/000110465925065781/tm2519601d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-065781
- JSON: https://secwatch.observer/filing/0001104659-25-065781.json
- Plain text: https://secwatch.observer/filing/0001104659-25-065781.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.